Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Negishi T, Furubayashi N, Nakagawa T, Nishiyama N, Kitamura H, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Okajima E, Nakamura M.
Negishi T, et al. Among authors: tomoda t.
Anticancer Res. 2021 Mar;41(3):1539-1545. doi: 10.21873/anticanres.14913.
Anticancer Res. 2021.
PMID: 33788747